Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (

@article{Hurteau2010RandomizedPI,
  title={Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (},
  author={Jean A. Hurteau and Mark F. Brady and Kathleen M. Darcy and William P. Mcguire and Pamela Edmonds and Michael Lawrence Pearl and Iouri M. Ivanov and Krishnansu S Tewari and Robert Mannel and Kristine Zanotti and Doris Mangiaracina Benbrook},
  journal={Gynecologic oncology},
  year={2010},
  volume={119 3},
  pages={
          444-50
        }
}
PURPOSE To compare progression-free survival (PFS), overall survival (OS) and toxicities of thalidomide versus tamoxifen and to evaluate serum vascular endothelial growth factor (VEGF) in biochemical-recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube carcinoma (EOC/PPC/FTC). METHODS Biochemical recurrence was defined as a rising CA-125 exceeding twice the upper limit of normal without evidence of disease as defined by RECIST 1.0 criteria. Women with FIGO stages… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Endocrine therapy in epithelial ovarian cancer.

  • Expert review of anticancer therapy
  • 2017
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

6 Steroid Hormones and Ovarian Cancer

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Update of randomized trials in recurrent disease.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5/EORTC 55955 trials)

GJ Rustin, van der BurgME
  • J Clin Oncol 2009;27(18S):793s
  • 2009
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…